The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients has been high-dose chemotherapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Tingxun, Zhang, Jie, Xu-Monette, Zijun Y., Young, Ken H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424456/
https://www.ncbi.nlm.nih.gov/pubmed/37580826
http://dx.doi.org/10.1186/s40164-023-00432-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424456/
https://www.ncbi.nlm.nih.gov/pubmed/37580826
http://dx.doi.org/10.1186/s40164-023-00432-z

Ejemplares similares